Drug Type Trispecific T-cell engager (TriTE) |
Synonyms QL 535, QL535 |
Target |
Action agonists, stimulants, inhibitors |
Mechanism CD2 agonists(T-cell surface antigen CD2 agonists), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Preclinical | United States | 28 Apr 2025 | |
Metastatic castration-resistant prostate cancer | Preclinical | China | 28 Apr 2025 |